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In the study entitled “Men Born in 1914,” a reduction of
pulse-wave amplitude during reactive hyperemia was found
to be predictive of long-term cardiovascular events (1). Of
particular note is the fact that these observations were made
many years before the whole concept of endothelium-
dependent vasoreactivity and its mediators was elaborated
(2). Therefore, this study was the first to subsequently
demonstrate the association between vascular function and
long-term clinical outcome. With a better understanding of
the underlying molecular mechanisms and different tech-
niques to examine endothelium-mediated vasoreactivity,
subsequent studies confirmed the prognostic significance of
endothelial dysfunction in both the coronary and the pe-
ripheral circulation (3–6).
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Impairment of endothelium-dependent vasorelaxation
has become a marker of endothelial dysfunction, although
endothelial dysfunction is, in fact, characterized by many
additional vascular abnormalities. According to the
response-to-injury theory, the currently prevailing pathoge-
netic concept of atherosclerosis, endothelial dysfunction is
both an initial and integral part of the inflammatory-
proliferative disease process in response to cardiovascular
risk factors such as hypertension, hypercholesterolemia,
diabetes mellitus, and smoking (7–9). Endothelial cell
dysfunction is, therefore, both a consequence and a media-
tor of the pathophysiologic action of cardiovascular risk
factors.
In this issue of the Journal, Ceravolo et al. (10) reported
on the association between pulse pressure and acetylcholine
(ACh)-stimulated forearm blood flow (FBF) in a cohort of
patients with untreated essential hypertension, promoting
pulse pressure as an independent risk factor for endothelial
dysfunction. Blood pressure measurements were performed
both during clinical visits as well as in an ambulatory
monitoring setting, and pulse pressure was calculated as the
difference between systolic and diastolic blood pressure.
Endothelium-dependent and endothelium-independent
FBF was measured during intra-arterial infusion of ACh
and sodium nitroprusside, respectively. Using univariate and
multivariate regression models, pulse pressure was found to
be independently and most strongly associated with peak
percent increase in FBF, accounting for one-third of the
variation in ACh-stimulated FBF.
This article (10) is important not only because of the
novelty of the findings, relating pulse pressure to
endothelium-dependent vasorelaxation for the first time in
humans, but even more so because of the potential impli-
cations of integrating these findings into clinical practice.
Elevated systolic blood pressure and pulse pressure have
been previously suggested to increase the risk of cardiovas-
cular morbidity and mortality (11,12). However, recent
subanalyses from multicenter trials such as the Multiple
Risk Factor Intervention Trial questioned the independent
prognostic value of pulse pressure (13).
Nevertheless, there are data available that underscore the
parallelism between pulse pressure and other cardiovascular
risk factors. For example, increase in pulse pressure reduced
the vasorelaxation response of rabbit carotid arteries to
ACh; the impairment in vasorelaxation was restored with
superoxide dismutase treatment, indicating the involvement
of oxidative stress (14). Furthermore, compared with lami-
nar flow, oscillatory and pulsatile flow patterns are associ-
ated with an increase in endothelial oxidative stress, result-
ing in impairment of endothelial function (15–17). Thus,
the pulsatile blood pressure component can affect the
function of the endothelium, independently from the other
blood pressure components.
Importantly, basal endothelial release of nitric oxide
(NO) can, in turn, affect arterial stiffness or elasticity
(18–21). By reducing NO bioavailability, an increase in
pulse pressure might, therefore, become self-escalating.
However, the initiating trigger for this vicious circle remains
hard to define. If the primary culprit is endothelial dysfunc-
tion, cardiovascular risk factors in general should also
increase pulse pressure by increasing arterial stiffness. Yet,
neither hypercholesterolemia nor diabetes mellitus or smok-
ing necessarily increases arterial stiffness (18,22,23). On the
contrary in old spontaneously hypertensive rats, an increase
in pulse pressure is usually subsequent to the development of
endothelial dysfunction (24), and for instance, mechanical
treatment of renovascular hypertension has been demon-
strated to result in normalization of systemic endothelial
function (8). The reciprocal relationship between pulse
pressure and endothelial function is, furthermore, supported
by the observation that antihypertensive drugs, such as
angiotensin-converting enzyme inhibitors, angiotensin II
receptor antagonists, calcium channel blockers, beta-
blockers, vasopeptidase inhibitors, and even diuretics have
been shown to reduce pulse pressure but also to improve
endothelial function, whereas drugs that improve endothe-
lial function, such as 3-hydroxy-3-methylglutaryl coenzyme
A reductase inhibitors, have been shown to reduce systemic
blood pressure and pulse pressure, as well (25–27). The
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interaction between pulse pressure and endothelial dysfunc-
tion, therefore, seems to relate not to cardiovascular risk
factors in general but rather uniquely to hypertension (28).
These considerations raise the question of whether pulse
pressure, endothelial dysfunction, or both should be rou-
tinely studied during diagnostic clinical evaluation, at least
of the hypertensive patient. Although blood pressure mea-
surements and calculation of pulse pressure are usually
readily available during the visit of the patient, 24-h blood
pressure monitoring may prove to be more representative
and accurate. Furthermore, blood pressure or pulse pressure
measurements alone may not be sufficient to assess the
cardiovascular risk of the patient, and specific evaluation of
endothelial function may be required for this purpose.
Further standardized studies will be required to determine
the sensitivity and specificity of pulse pressure elevation for
the assessment of endothelial dysfunction. The study by
Ceravolo et al. (10) in this issue of the Journal is an
important milestone on the way to developing a more
effective diagnostic work-up of hypertensive patients and
will need to be confirmed in larger-scale studies.
Taken together, a number of studies have underscored
the association of long-term outcome with both endothelial
function and pulse pressure. In the current study, Ceravolo
et al. (10) provide further evidence for a direct association
between pulse pressure and the function of the endothelial
monolayer in hypertensive patients. As outlined by prior
studies, this link might relate to a decrease in NO bioavail-
ability, which results in both impairment in endothelial
function and increased arterial stiffness. Therefore, it is not
surprising to find that increased pulse pressure and endo-
thelial dysfunction often coexist in hypertensive patients.
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